Absci (ABSI) Other Non-Current Liabilities (2020 - 2026)
Absci (ABSI) posted Other Non-Current Liabilities of $806000.0 for Q1 2026, down 21.21% sequentially from $1.0 million in Q4 2025, and down 52.17% YoY from $1.7 million in Q1 2025.
Absci (ABSI) Other Non-Current Liabilities (2020 - 2026) Analysis & Trends
Absci has reported Other Non-Current Liabilities for 7 years, with the latest figure at $806000.0 in Q1 2026.
- Quarterly Other Non-Current Liabilities fell 52.17% year-over-year to $806000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $806000.0 (down 52.17% YoY) and the FY2025 annual result came in at $1.0 million, up 669.17% from the prior year.
- Other Non-Current Liabilities declined to $806000.0 in Q1 2026 per ABSI's latest filing, from $1.0 million in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $1.8 million in Q3 2025 and troughed at $15000.0 in Q2 2024.
- A 5-year average of $560785.7 and a median of $224500.0 in 2022 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2022 and 2025: Other Non-Current Liabilities tumbled 99.73% in 2022, then soared 9780.0% in 2025.
- Over 5 years, Other Non-Current Liabilities stood at $35000.0 in 2022, then soared by 742.86% to $295000.0 in 2023, then slumped by 54.92% to $133000.0 in 2024, then surged by 669.17% to $1.0 million in 2025, then slipped by 21.21% to $806000.0 in 2026.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $806000.0, $1.0 million, and $1.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Absci | 1.58 Bn | 1.37 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.31 Mn |
| Mar 31, 2026 | 806,000.00 |
| Dec 31, 2025 | 1.02 Mn |
| Sep 30, 2025 | 1.79 Mn |
| Jun 30, 2025 | 1.48 Mn |
| Mar 31, 2025 | 1.69 Mn |
| Dec 31, 2024 | 133,000.00 |
| Sep 30, 2024 | 31,000.00 |
| Jun 30, 2024 | 15,000.00 |
| Mar 31, 2024 | 78,000.00 |
| Dec 31, 2023 | 295,000.00 |
| Dec 31, 2022 | 35,000.00 |
| Sep 30, 2022 | 33,000.00 |
| Jun 30, 2022 | 227,000.00 |
| Mar 31, 2022 | 222,000.00 |
| Dec 31, 2021 | 12.16 Mn |
| Sep 30, 2021 | 12.13 Mn |
| Jun 30, 2021 | 15.00 Mn |
| Dec 31, 2020 | 749,000.00 |